Join the club for FREE to access the whole archive and other member benefits.

Harpal Kumar

Head of Johnson & Johnson Innovation, EMEA at Johnson & Johnson.

Harpal is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Center in London.

He oversees a portfolio of co-investments and collaborations across the region and works to grow the Innovation Center’s networks within the EMEA innovation community – which includes working, and building relationships with academia, venture capital, entrepreneurs, NGOs, and governmental organisations.

Before joining Johnson & Johnson Innovation, Harpal’s career has been largely focused on improving healthcare outcomes through innovation. He spent 15 years with Cancer Research UK (CRUK) and served as the organisation’s Chief Executive from April 2007 until June 2018. Prior to this, he was Chief Operating Officer & Executive Director of Development at CRUK and served as Chief Executive of Cancer Research Technology (a subsidiary of CRUK).

Visit website: https://jnjinnovation.com/team/sir-harpal-kumar-1

 Login to view link, or join the club to get full access to all resources and other benefits.

See also: Company Johnson & Johnson - Largest healthcare company that develops medical devices, pharmaceuticals, and consumer packaged goods

Harpal Kumar News

100,000 Genomes Project hits halfway milestone

Cancer Research UK - 21-Feb-2018

Project to uncover the genetic causes of diseases began in 2012. 100,000 Genomes Project aims to...

Read more...

Personalised breast cancer programme launches in Cambridge

Drug Target Review - 18-Nov-2016

Cancer Research UK Cambridge Institute’s programme will map patients’ DNA and RNA to tailor treat...

Read more...

Cancer study aiming to end chemotherapy

BBC - 21-Jan-2016

First patients have their DNA analysed in massive study. Includes three sisters who developed br...

Read more...

‘Half of UK people’ will get cancer

BBC - 04-Feb-2015

Analysis suggests that one in two people in the UK will be diagnosed with cancer at some point in...

Read more...